1 recall leaflet contains 247.25 mg dried iron (II) sulphate (corresponding to 80 mg iron). Otherwise. Ingredient: Tablet core: maltodextrin, microcrystalline cellulose, ammonium methacrylate copolymer B (Eudragit RS 30D), ammonium methacrylate copolymer A (Eudragit RL 30D), talc, triethyl citrate, glycerol dibehenate (Ph. Eur.). Tablet coating: Sepifilm LP010 (hypromellose, microcrystalline cellulose, stearic acid), yellow iron (III) oxide (E172), red iron (III) oxide (E172), titanium dioxide, triethyl citrate.
application
Iron deficiency therapy.
Contraindications
Iron overload, especially normo- or hypersideremic anemia such as thalassemia, refractory anemia, anemia due to bone marrow failure. Children under 10 years.
pregnancy
App. possible. Do not use a high dose of 2 x 1 ret.
Side effects
Common: constipation, diarrhoea, bloated stomach, abdominal pain, discoloured stools, nausea. Occasionally: laryngeal oedema. Abnormal stools, dyspepsia, vomiting, gastritis. Pruritus, erythematous rash. Not known: hypersensitivity, urticaria, lung necrosis (bronchial necrosis)**, pulmonary granulomas**, bronchostenosis**. Tooth discolouration*, mouth ulcers*, oesophageal lesions**, gastrointest. melanosis. Cases of gastrointest. Melanosis have been reported in the literature in the elderly Patient with chronic e. Kidney disease. reported with unknown frequency; these patients were due to diabetes u./od. High blood pressure treated with multiple drugs against these diseases and received at the same time. Iron preparation for the treatment of associated anemia. False positive response. for the benzidine sample or. Similar tests are possible to detect occult bleeding in the stool. Withdraw Tardyferon 3 days before the examination. * Mouth ulcers and tooth discoloration in connection with improper administration when the tablets are chewed, sucked or left in the mouth for a long time. ** B. Pat., Especially with the elderly. Pat. Or Pat. With difficulty swallowing there is also a risk of esophageal lesions, bronchial granulomas and/or bronchial necrosis, which can lead to brochostenosis, after aspiration of tablets with iron sulphate. with difficulty swallowing there is also a risk of esophageal lesions, bronchial granulomas and/or bronchial necrosis, which can lead to brochostenosis, after aspiration of tablets with iron sulphate. with difficulty swallowing there is also a risk of esophageal lesions, bronchial granulomas and/or bronchial necrosis, which can lead to brochostenosis, after